Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2007-03-13
2007-03-13
Campell, Bruce R. (Department: 1648)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C424S232100, C424S204100, C424S202100, C424S201100, C424S093600, C424S001110, C424S278100, C435S237000, C435S235100
Reexamination Certificate
active
10440073
ABSTRACT:
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen.
REFERENCES:
patent: 3914408 (1975-10-01), Mebus
patent: 4072565 (1978-02-01), Weiss et al.
patent: 4191745 (1980-03-01), Mayr et al.
patent: 5155020 (1992-10-01), Paoletti
patent: 5185146 (1993-02-01), Altenburger
patent: 5338683 (1994-08-01), Paoletti et al.
patent: 5494807 (1996-02-01), Paoletti et al.
patent: 5770212 (1998-06-01), Falkner et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5843456 (1998-12-01), Paoletti et al.
patent: 6204250 (2001-03-01), Bot et al.
patent: 6440422 (2002-08-01), Sutter et al.
patent: 6605465 (2003-08-01), Paoletti
patent: 6663871 (2003-12-01), McMichael et al.
patent: 6685950 (2004-02-01), Weber et al.
patent: 6761893 (2004-07-01), Chaplin et al.
patent: 6805870 (2004-10-01), Mayr
patent: 6869793 (2005-03-01), Cardosa et al.
patent: 6913752 (2005-07-01), Chaplin et al.
patent: 2002/0022268 (2002-02-01), Xu et al.
patent: 2003/0138454 (2003-07-01), Hill et al.
patent: 2004/0131594 (2004-07-01), McMichael et al.
patent: WO 90/12882 (1990-11-01), None
patent: WO 92/05246 (1992-04-01), None
patent: WO 95/22978 (1995-08-01), None
patent: WO 97/02355 (1997-02-01), None
patent: WO9702355 (1997-02-01), None
patent: WO 98/04680 (1998-02-01), None
patent: WO 98/17283 (1998-04-01), None
patent: WO 98/56919 (1998-12-01), None
patent: WO 99/07869 (1999-02-01), None
patent: WO 00/28016 (2000-05-01), None
patent: WO 01/68820 (2001-09-01), None
patent: WO 02/24224 (2002-03-01), None
patent: WO 02/42480 (2002-05-01), None
Eo et al, The Journal of Immunology 166:5473-5479, May 2001.
Holzer et al (Journal of Virology 73:4536-4542, 1999).
Antoine et al, Virology 244:365-96, 1998.
Schieflinger et al, PNAS 89:9977-81, 1992.
Merchlinsky et al, Virology 190:522-6, 1992.
Gilbert et al, Biol. Chem. 380:299-303, 1999.
Moss et al. “Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.” Advances in Experimentaly Medicine and Biology 397:7-13, 1996.
Wyatt et al (PNAS 101:4590-4595, 2004).
Earl et al (Nature 428:182-185, 2004).
Stittelaar et al. Vaccine 19:3700-3709, 2001.
Watts et al (Nature Medicine 5:427-430, 1999).
Siegrist et al (Vaccine 16: 1473-1478, 1998).
Suarez et al (Obstetrics & Gynecology 100:87-93, Jul. 2002).
Zhu et al (Virology 276:202-213, 2000).
Roberts (Drug Discovery Today 7:936-937, 2002).
Monteil et al (Journal of General Virology 78:3303-3310, 1997).
Siegrist (Vaccine 19:3331-3346, 2001; International Reviews of Immunology 19:195-219, 2000.
Mayr, A., Zbl Vet B 23, 417-430 (1976).
Blanchard, J.T., et al., Journal of General Virology, 79, 1159-1167 (1998).
Caroll, W.M. and Moss, B., Virology 238, 198-211 (1997).
Meyer, H., et al., Journal of general virology, 72, 1031-1038 (1991).
Bender, et al., Journal of Virology, vol. 70, No. 9, pp. 6418-6424 (Sep. 1, 1996).
Schneider, et al. (1998), Nature Medicine 4, 397-402.
Sutter, et al. (1994), Vaccine 12, 1032-1040.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Order No. 28; Denying in Part Complainant's Motion for Summary Determination and Denying in Part Respondent's Motion for Summary Determination, United States International Trade Commission, Washington, D.C., Apr. 18, 2006.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Nucleotide alignment of MVA-AntionevsAcambis 3000 MVAvsMVA-BN, Aug. 31, 2005.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Respondent's Amended Pre-Hearing Brief, United States International Trade Commission, Washington, D.C., May 8, 2006.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 377-TA-550,Respondent's Opposition to Compainant's Motion for Sanctions, United States International Trade Commission, Washington, D.C., Jul. 7, 2006.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Respondent's Opposition to Compainant's Motion for Summary Determination of Infringement, 10439953.051603 United States International Trade Commission, Washington, D.C.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Respondent's Rebuttal to Compainant's Proposed Conclusions of Law, United States International Trade Commission, Washington, D.C., Jun. 14, 2006.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant Bavarian Nordic's Motion for Sanctions and Memorandum in Support of its Motion, United States International Trade Commission, Washington, D.C., Jun. 21, 2006 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Memorandum in Opposition to Respondent's Motion for Summary Determination, United States International Trade Commission, Washington, D.C., Mar. 30, 2006 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant Bavarian Nordic's Memorandum in Support of its Motion in Limine, United States International Trade Commission, Washington, D.C., May 1, 2006 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant's Post Hearing Brief, United States International Trade Commission, Washington, D.C., Apr. 28, 2006 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant Bavarian Nordic's Motion for Summary Determination of Infringement of the '893 Patent, its Memorandum of Law in Support of its Motion, its Statement of Undisputed Facts in Support of its Motion and Supporting Exhibits, United States International Trade Commission, Washington, D.C., Mar. 20, 2005 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant's Post Hearing Reply Brief, United States International Trade Commission, Washington, D.C., Jun. 14, 2006 (Public Version).
Bender, et al., Oral Immunization with a Replication-Deficient Recombinant Vaccinia Virus Protects Mice Against Influenza. (1996) J. Virology, vol. 70(9):6418-6424.
JAX® Mice Data Sheet, Product Information for Stock No. 001913, The Jackson Laboratory, Bar Harbor, Maine, USA.
List of Documents Relied on in European Opposition Proceedings, two (2) pages.
Drillien, et al, Attenuation Profile Comparison of Various MVA Strains. Study Report, Institut de Géné
Chaplin Paul
Howley Paul
Meisinger Christine
Bavarian Nordic A/S
Blumel Benjamin P.
Campell Bruce R.
Hueschen and Sage
LandOfFree
Modified vaccinia ankara virus variant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified vaccinia ankara virus variant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified vaccinia ankara virus variant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3789911